LivaNova (NASDAQ:LIVN) Lifted to Outperform at Robert W. Baird

Robert W. Baird upgraded shares of LivaNova (NASDAQ:LIVN) from a neutral rating to an outperform rating in a research note issued to investors on Tuesday morning, Marketbeat.com reports. They currently have $66.00 target price on the stock, up from their previous target price of $55.00.

LIVN has been the topic of several other reports. Needham & Company LLC upped their target price on LivaNova from $72.00 to $75.00 and gave the company a buy rating in a report on Wednesday, July 31st. Stifel Nicolaus increased their price target on LivaNova from $70.00 to $72.00 and gave the stock a buy rating in a report on Thursday, July 25th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of Buy and a consensus target price of $70.80.

LivaNova Stock Performance

LivaNova stock opened at $50.75 on Tuesday. The business has a 50 day moving average of $48.85 and a 200-day moving average of $53.37. LivaNova has a 1 year low of $42.75 and a 1 year high of $64.47. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.45 and a quick ratio of 2.94. The company has a market capitalization of $2.75 billion, a P/E ratio of -84.58 and a beta of 1.00.

LivaNova (NASDAQ:LIVN) last announced its earnings results on Wednesday, July 31st. The company reported $0.81 EPS for the quarter, beating the consensus estimate of $0.66 by $0.15. LivaNova had a positive return on equity of 13.77% and a negative net margin of 1.37%. The business had revenue of $318.60 million for the quarter, compared to analysts’ expectations of $305.05 million. On average, equities research analysts predict that LivaNova will post 2.58 earnings per share for the current year.

Institutional Investors Weigh In On LivaNova

Institutional investors and hedge funds have recently bought and sold shares of the stock. Hexagon Capital Partners LLC increased its position in shares of LivaNova by 117.8% during the 2nd quarter. Hexagon Capital Partners LLC now owns 684 shares of the company’s stock valued at $37,000 after purchasing an additional 370 shares during the last quarter. Fifth Third Bancorp increased its holdings in LivaNova by 97.1% in the 2nd quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock worth $37,000 after acquiring an additional 332 shares during the last quarter. Lazard Asset Management LLC purchased a new stake in LivaNova in the 1st quarter worth about $84,000. Canada Pension Plan Investment Board purchased a new stake in LivaNova in the 2nd quarter worth about $88,000. Finally, Acadian Asset Management LLC purchased a new stake in LivaNova in the 1st quarter worth about $94,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.